

COVID-19 Press Briefing

July 8, 2021







Daily Change in COVID-19 Cases, US

January 22, 2020 – July 6, 2021

TOTAL Cases Reported Since 1/22/20

33,582,352

NEW Cases Reported to CDC on 7/6/21

14,137

Change in 7-Day Case Average


+10.8%

Current 7-Day Case Average (6/30/21 - 7/6/21)

13,859

Prior 7-Day Case Average (6/23/21 - 6/29/21)

12,512







New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – July 5, 2021

Patients Currently Hospitalized with COVID on 7/5/21

12,637

New Admissions on 7/5/21

1,907

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


+6.8%

Current 7-Day Average of New Admissions (6/29/21 - 7/5/21)

1,991

Prior 7-Day Average of New Admissions (6/22/21 - 6/28/21)

1,864







Daily Change in COVID-19 Deaths, US

January 22, 2020 – July 6, 2021

TOTAL Deaths Reported Since 1/22/2020

603,656

NEW Deaths Reported to CDC on 7/6/21

224

Change in 7-Day Death Average

-13.1%

Current 7-Day Death Average (6/30/21 - 7/6/21)


184

Prior 7-Day Death Average (6/23/21 - 6/29/21)

211

Forecasted Total Deaths by 7/31/21

610,000 to 616,000




*7-day averages exclude historical cases reported retroactively by states






Counties with Case Rates ≥100/100,000



Counties with Case Rates ≥100/100,000 and <40% of the Population Fully Vaccinated



Estimates for 50 states, D.C., and Puerto Rico. Time period: Fri Jul 2, 2021. Data source: COVID Data Tracker. Hawaii and Texas are excluded as county-level vaccination information is unavailable. California counties with <20k population, Virginia counties (independent cities) that did not report data, and the Valdez-Cordova Census Area in Alaska also are excluded. Excluded counties are shaded in gray.





mRNA Vaccine Effectiveness Against SARS-CoV-2 Delta Variant in the U.K.

- Real-world studies
 - PCR-confirmed infection: Scotland, 2 doses
 Pfizer vaccine: 79%
 - Symptomatic infection: England, 2 doses Pfizer vaccine: 88%
 - Hospitalization: England, 2 doses Pfizer vaccine: 96%



Indirect Evidence for Effectiveness of Johnson & Johnson Vaccine Against SARS-CoV-2 Delta Variant

- J&J vaccine and Oxford-AstraZeneca vaccine use similar adenovirus vectors
- Oxford-AstraZeneca real-world effectiveness data from United Kingdom
 - 60% against PCR-confirmed infection with Delta variant (Scotland)
 - 60% against symptomatic disease from Delta variant (England)
 - 92% against hospitalization from Delta variant (England)



Johnson & Johnson Vaccine-Induced **Antibodies Neutralize Delta Variant in Laboratory Tests**



Ad26.COV2.S Elicited Neutralizing Activity Against Delta and Other SARS-CoV-2 Variants of Concern

M Jongeneelen, B Brandenburg et al.

- Tests of blood of people vaccinated with single dose of the J&J vaccine show that the Delta variant and other variants are effectively neutralized
- Neutralization at a higher level than with Beta variant in South Africa where high J&J vaccine efficacy against severe/critical disease was demonstrated





THE PREPRINT SERVER FOR HEALTH SCIENCES

Posted July 7, 2021

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

DH Barouch, H Schuitemaker et al.

- Robust coverage of SARS-CoV-2 Delta variant and other variants
- Minimal decline of antibody and T-cell responses over 8 months
- Expansion of neutralizing antibody breadth and improved coverage of variants over time
- Pfizer, Moderna, J&J vaccines show similar antibody responses at 6-8 months; all 3 vaccines cover Delta and other variants





The New York Times

July 7, 2021

The world is worried about the Delta virus variant. Studies show vaccines are effective against it.







THE WHITE HOUSE WASHINGTON

WH.GOV